The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.
PI Healthsciences acquired Archimica S.p.A, an API manufacturer located in Lodi, Italy, on April 28, 2023, with the intention to provide Archimica the opportunity to integrate their value chain and enhance the security of supplies by using PI’s technological excellence, according to the press release.
PI Healthscienes, a specialty chemical company in India, has more than 3500 employees, three formulation facilities, and 15 multi-product plants. The company’s facilities integrate process development with in-house engineering. It’s R&D facility in Udaipur has a dedicated team of more than 500 scientists and chemists. The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.
“We are excited about this acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space. Our unique ability to build concrete offerings from abstract situations and leverage our capabilities across complex chemistries in the value chain will once again help create a differentiated value proposition for our stakeholders,” said Mayank Singhal, Vice Chairperson & Managing Director of PI Industries Ltd., in a press release. “This acquisition aligns with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet. We are excited to welcome the talented team from Archimica to the PI family. We look forward to deploying all our combined expertise towards unique value delivery for our customers. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity.”
Source: Archimica
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.